Furthermore, when looking at proxy subtypes, non-screeners are at higher odds of developing HER2-overexpressed cancers (ORHER2-overexpressed vs luminal A (reference): 1.39 [1.05–1.83], p = 0.022) and patients who are unaware have higher odds of developing luminal B (HER2-negative) cancers (ORluminal B [HER2-negative] vs luminal A (reference): 1.44 [1.01–2.05], p = 0.041). Here, ERBB2 is linked to cancer.